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Abstract
Introduction: Zoledronic acid is a highly effective treatment in Paget’s disease for persistent bone pain and
prevention of further progression of the disease. The commonest electrolyte abnormality is hypocalcemia. To the
best of our knowledge this is the first case of hyperkalemia secondary to zoledronic acid to be published in the
world literature. The commonest arrhythmia related to zoledronic acid is atrial fibrillation.
Case presentation: We describe the case of an 80-year-old Caucasian man, with a history of ischemic heart
disease, who had an in-hospital cardiac arrest related to hyperkalemia. Increasing potassium levels were noted
following his first zoledronic acid infusion for symptomatic control of bone pain secondary to Paget’s disease. Our
patient suffered a cardiac arrest 10 days following the zoledronic acid infusion. Our patient’s biochemistry and
electrocardiogram output were monitored until his death 26 days after his cardiac arrest. Our patient developed
paroxysmal atrial fibrillation in the post-resuscitation period and there was persistent hyperkalemia that required
prolonged treatment with calcium resonium. All other possible causes of hyperkalemia were excluded.
Conclusion: In our patient’s case persistent hyperkalemia and life-threatening arrhythmias were associated with
use of zoledronic acid. These side effects have not been reported before and the causative mechanism is far from
clear as there are no obvious systemic effects of zoledronic acid. The combination of zoledronic acid with
predisposing factors such as structural heart disease might account for the clinical picture we witnessed. As a
result, electrolyte monitoring should be adopted early in zoledronic acid use. Further studies are required to
elucidate the underlying mechanism of hyperkalemia and identify the target group of patients where zoledronic
acid can be safely administered. Great caution is advised in patients with underlying heart conditions.
Introduction
Four million people are affected by Paget’s disease
worldwide. Zoledronic acid was licensed for the treat-
ment of Paget’s disease in the UK in 2005 and is highly
effective providing a prolonged remission after a single
intravenous infusion. In the HORIZON (’Health Out-
comes and Reduced Incidence with Zoledronic acid
ONce yearly’) study, involving 10,000 patients, flu-like
symptoms, atrial fibrillation and transient renal dysfunc-
tion were the commonest side effects. Low calcium,
phosphate, magnesium and potassium levels are com-
mon electrolyte disturbances described in the literature.
One death related to hyperkalemia and acute renal
failure in an older patient with osteoporosis and bone
metastases following his second zoledronate infusion has
been reported to the Medicines and Healthcare Products
Regulatory Agency (MHRA) [1]. Hyperkalemia is also
documented as a rare side effect on the producing com-
pany’s database. To the best of our knowledge our
report is the first published case.
Zoledronic is a very useful treatment for a large num-
ber of patients with a variety of conditions. Potentially
fatal side effects, which may remain unnoticed as the
majority of patients receive their treatment in an out-
patient setting, should become more widely known and
efforts should be made to identify and monitor high-risk
patients.
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An 80-year-old Caucasian man, who was admitted to
our facility for symptomatic control of bone pain sec-
ondary to Paget’s disease, had an in-hospital cardiac
arrest related to hyperkalemia following his first zole-
dronic acid infusion. Despite having had coronary artery
bypass grafting for myocardial infarction in the past,
there were no ongoing cardiac symptoms. Progressively
increasing potassium levels were noted after a single 5
mg zoledronic acid infusion (Figure 1). His renal func-
tion remained normal. On admission his potassium level
was 4.9 mmol/L (normal range: 3.6 to 5 mmol/L),
sodium level 136 mmol/L (normal range 135 to 145
mmol/L), urea level 11.3 mmol/L (normal range 1.7 to
8.3 mmol/L), creatinine level 85μmol/L (normal range
58 to 96μmol/L), estimated glomerular filtration rate
(eGFR) >60 mL/minute/1.73 m
2, calcium level 2.27
mmol/L (normal range 2.1 to 2.6 mmol/L), phosphate
level 1.21 mmol/L (normal range 0.8 to 1.4 mmol/L),
25-hydroxyvitamin D level 36 nmol/L (normal range 80
to 150 nmol/L) and alkaline phosphatase level 4973 IU/
L (normal range 42 to 128 IU/L). The night prior to his
cardiac arrest, his potassium level reached 6.3 mmol/L
and our patient received an infusion of insulin and dex-
trose, as well as calcium gluconate, that resulted in his
potassium level being reduced to 5.9 mmol/L. His elec-
trocardiogram results showed bifascicular block and
atrial flutter with variable block and a heart rate of 75
beats/minute. His simultaneous calcium level was 2.15
mmol/L and magnesium level was 1.17 mmol/L (normal
range 0.7 to 1.0 mmol/L).
Our patient suffered a slow pulseless electrical activity
(PEA) cardiac arrest 10 days following the zoledronic
acid infusion, lost his cardiac output briefly, received 1
mg of adrenaline and 3 mg of atropine and was resusci-
tated according to the standard adult life support proto-
cols. His post-resuscitation electrocardiogram showed
irregular broad complex tachycardia. His post-cardiac
arrest blood results were as follows: potassium 7.3 mmol/
L, calcium 2.05 mmol/L (albumin 31 g/L), phosphate 1.3
mmol/L, magnesium 1.17 mmol/L, hydrogen ions 57
nmol/L (normal range 35.5 to 44.5 nmol/L), base excess
-8.6 mmol/L (normal range -5 to +3 mmol/L) and lactate
7.8 mmol/L (normal range 0.4 to 2.2 mmol/L). As part of
his post-resuscitation care he received a further insulin/
dextrose infusion and calcium gluconate.
Following cardiac arrest he maintained his blood pres-
sure and was transferred to the high dependency unit
(HDU) for monitoring and further management. Repeat
blood results showed potassium 4.3 mmol/L, calcium
1.98 mmol/L, hydrogen ions 38 nmol/L, base excess -1.8
mmol/L, bicarbonate 29 mEq/L (normal range 18 to 23
mEq/L), lactate 3.3 mmol/L, creatinine 59μmol/L, eGFR
>60 mL/minute/1.73 m
2. He was on slow release verapa-
mil for angina (he was b-blocker intolerant because of
asthma) that was temporarily discontinued. While in the
high-dependency unit he remained in paroxysmal atrial
fibrillation/flutter (heart rate 110 to 140 beats/minute).
The right bundle branch block noted two weeks prior to
the cardiac arrest persisted.
He also developed acute delirium related to hypoxia
secondary to pulmonary edema, for which he received
non-invasive continuous positive airway pressure
respiratory support. His echocardiogram showed mild
left ventricular dysfunction, dilated atria and mild pul-
monary and tricuspid regurgitation with mild pulmonary
hypertension. His troponin I level was mildly elevated,
which was not considered to be significant.
Figure 1 Potassium levels prior and after zoledronic acid infusion (day 0).
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c a t i o nt h a th a dr e c e n t l yb e e na d m i n i s t e r e dt h a tc o u l db e
associated with the above biochemical results was zoledro-
nic acid. All other possible causes of hyperkalemia were
excluded (Table 1). Thyroid function and short synacthen
test results were normal. After his discharge from the
high-dependency unit his potassium was maintained
within the normal range on calcium resonium and his
hypocalcemia persisted. Verapamil was restarted in
increasing doses to control his ventricular rate. Our
patient died of pneumonia 26 days after his cardiac arrest.
He had paroxysmal atrial fibrillation until his death.
Discussion
Zolendronic acid is a bisphosphonate used in patients
with bone metastases from solid tumors, osteolytic
lesions in multiple myeloma, osteoporosis and Paget’s
disease [2]. Zoledronic acid preferentially accumulates in
bone and is excreted unchanged in the urine with a
half-life of 146 hours [3]. It causes disruption of the 3-
hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA)
reductase pathway that is essential for the production of
lipid-anchoring cell membrane proteins. Cholesterol
metabolites participate in the signaling pathway for
interleukin-6 (IL-6)-mediated inflammation [4]. Eleva-
tion of tumor necrosis factor and IL-6 occurs one to
two days following intravenous administration of
bisphosphonates [5] and can increase the incidence of
atrial fibrillation [6]. Atrial fibrillation is more common
with alendronate in patients taking statins (HMG-CoA
inhibitors) [7]. Black et al. reported a statistically signifi-
cant difference (P = 0.003) in the occurrence of serious
atrial fibrillation in the zoledronic acid group 9 to 11
days after the infusion compared to placebo, although
there was no difference in the incidence of all types of
atrial fibrillation between the two groups [8]. In the
HORIZON trial, involving post-menopausal women
with osteoporosis, atrial fibrillation occurred more than
30 days after the infusion. Our patient developed bifasci-
cular block and atrial flutter prior to his cardiac arrest
and paroxysmal atrial fibrillation and flutter in the post-
resuscitation period. Atrial remodeling and fibrosis have
been suggested as likely mechanisms for the develop-
ment of atrial fibrillation after bisphosphonate adminis-
tration [9]. In our case no arrhythmia had been
clinically diagnosed prior to the infusion, despite the
history of ischemic heart disease.
Niemann and Cairns showed that successfully resusci-
tated animals do not exhibit electrolyte abnormalities
[10] and as a result the increased potassium level in our
case is thought to be the cause and not the result of the
cardiac arrest.
Conclusion
Zoledronic acid has unknown side effects, despite having
been tested prior to its wide clinical use. In our patient
persistent hyperkalemia and life-threatening arrhythmias
were associated with zoledronic acid infusion. These side
effects have not been previously published and the causa-
tive mechanism is unclear, as zoledronic acid appears to
be bone specific with no obvious systemic effects. In our
case hyperkalemia was an early side effect that persisted
for approximately four weeks. Atrial fibrillation is a side
effect documented in the literature that was also present
in our case. Zoledronic acid in relation to ischemic heart
disease and structural heart abnormality might be more
commonly associated with the clinical picture we
observed. Heckbert et al. stated that there was no differ-
ence in the risk of developing atrial fibrillation with alen-
dronate in the subgroup with history of cardiovascular
disease [7]. When zoledronic acid is used, close monitor-
ing of electrolytes is recommended. The correct time for
initiating the monitoring and its duration are uncertain.
Further investigation as to the mechanisms underlying
the development of hyperkalemia, and arrhythmias in
association with zoledronic acid would be of benefit.
Caution would seem necessary in using zoledronic acid
in patients with known heart disease.
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Table 1 Causes of hyperkalemia
Category Cause
Excessive potassium
intake
Potassium-containing dietary supplements,
intravenous potassium infusion
Ineffective potassium
renal excretion
Renal impairment
Hormonal Addison’s disease, congenital adrenal
hyperplasia, aldosterone deficiency, type IV
renal tubular acidosis
Intra-cellular potassium
release
Rhabdomyolysis, tumor lysis syndrome, blood
transfusion, hemolysis, beta blockers, digoxin
toxicity, low insulin levels
Medications Angiotensin-converting enzyme inhibitors,
amiloride, spironolactone, non-steroidal anti-
inflammatory drugs, ciclosporin, tacrolimus,
trimethoprim, pentamidine, heparin
Pseudohyperkalemia Hemolysis during venipuncture,
thrombocytosis, leukocytosis, polycythemia
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